Samsrita Labs Ltd
₹ 22.0
-0.14%
31 Oct
- close price
About
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Key Points
- Market Cap ₹ 50.0 Cr.
- Current Price ₹ 22.0
- High / Low ₹ 26.0 / 12.2
- Stock P/E
- Book Value ₹ 6.51
- Dividend Yield 0.00 %
- ROCE -1.79 %
- ROE -2.13 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 3.38 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -16.8%
- Promoter holding is low: 31.4%
- Company has a low return on equity of -3.24% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 3.97 | 3.69 | 1.28 | 0.62 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | |
| 0.01 | 4.03 | 3.73 | 1.61 | 1.64 | 4.13 | 3.46 | 0.92 | 0.43 | 1.01 | 0.25 | 0.26 | 5.34 | |
| Operating Profit | -0.01 | -0.06 | -0.04 | -0.33 | -1.02 | -2.23 | -2.03 | -0.91 | -0.41 | -0.99 | -0.25 | -0.26 | -5.34 |
| OPM % | -1.51% | -1.08% | -25.78% | -164.52% | -117.37% | -141.96% | -9,100.00% | -2,050.00% | -4,950.00% | ||||
| 0.08 | 0.09 | 0.05 | 0.01 | 0.00 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.49 | -0.70 | -0.25 | -0.26 | -5.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.50 | -0.71 | -0.25 | -0.26 | -5.35 | |
| EPS in Rs | 0.13 | 0.06 | 0.02 | -0.31 | -0.87 | -1.55 | -1.28 | -0.52 | 1.01 | -0.48 | -0.17 | -0.18 | -2.45 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | % |
| TTM: | -2040% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -13% |
| 3 Years: | -10% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -1% |
| 3 Years: | -3% |
| Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.39 | 5.39 | 5.39 | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 22.75 |
| Reserves | -1.62 | -1.60 | -1.58 | -1.90 | 0.11 | -1.01 | -2.38 | -3.01 | -1.51 | -2.22 | -2.47 | -2.72 | -7.94 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.32 | 1.79 | 2.34 | 2.74 | 2.08 | 2.20 | 2.43 | 1.66 | |
| 0.48 | 2.54 | 1.74 | 0.13 | 0.36 | 1.11 | 2.71 | 3.09 | 1.16 | 0.96 | 1.10 | 1.16 | 1.03 | |
| Total Liabilities | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.68 | 17.50 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 5.26 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.92 | 2.15 | 3.03 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 | 0.00 |
| Investments | 0.85 | 0.00 | 0.00 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 9.42 |
| 3.40 | 6.33 | 5.55 | 3.62 | 6.42 | 8.17 | 9.00 | 9.08 | 9.06 | 7.49 | 7.50 | 7.55 | 2.82 | |
| Total Assets | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.68 | 17.50 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | -0.76 | -0.02 | -0.06 | -3.28 | -3.46 | -1.07 | -0.34 | -0.40 | 0.66 | -0.13 | -0.23 | |
| -0.85 | 0.85 | 0.00 | -4.87 | -0.94 | -1.26 | -0.89 | -0.23 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.85 | 0.00 | 0.00 | 4.87 | 4.53 | 4.40 | 1.97 | 0.55 | 0.40 | -0.67 | 0.13 | 0.22 | |
| Net Cash Flow | 0.00 | 0.09 | -0.02 | -0.06 | 0.31 | -0.32 | 0.01 | -0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 528.65 | 498.54 | 932.46 | 1,689.60 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Inventory Days | 0.00 | 0.00 | 0.00 | 608.33 | 0.00 | 0.00 | ||||||
| Days Payable | 365.00 | |||||||||||
| Cash Conversion Cycle | 528.65 | 498.54 | 932.46 | 1,932.93 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Working Capital Days | 296.96 | 328.40 | 903.95 | 2,254.76 | 737.68 | 658.53 | 60,590.00 | 58,765.00 | 46,172.50 | |||
| ROCE % | 2.11% | 0.79% | 0.26% | -5.26% | -10.08% | -16.39% | -13.27% | -5.43% | 9.87% | -4.56% | -1.71% | -1.79% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 Oct - Publication of un-audited Financial Results for the quarter and half year ended 30th September, 2025
- Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th September, 2025 25 Oct
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 25.10.2025
25 Oct - Board approved Q2/H1 results; bought patent for Rs2.00cr; preferential issue Rs3.39cr; write-offs/provisions ~Rs2.59cr/2.09cr.
-
Board Meeting Intimation for Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2025
21 Oct - Board meeting on 25 Oct 2025 to consider unaudited standalone and consolidated Q2/H1 results ended 30 Sep 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-09-2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services:[1][2]
a) Stem Cell R&D:
Stem Cell Research & Therapy,
Regenerative Medicine, Bio-artificial
organ scaffolds development, nano-biotechnology, Nano-formulation of
cancer Drugs, Molecular genetics,
and Molecular virology, Stem cell
and Cord blood banking
b) New Drug Discovery:
Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease
c) RNA Interference:
For developing a new panel of miRNAs
as a novel Bio Marker
d) Medical Devices:
Extra-corporeal liver support devices, Bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, extra-corporeal devices, etc.
e) Molecular Diagnostics:
DNA, RNA, and chromosomal based tests
and Pre-natal and pre-implantation genetic diagnostics, etc.
f) Contract Research Organization:
Synthetic Chemistry, Medicinal Chemistry, Drug Development, API’s process research, scale-up activity, Natural products research, and Analytical services